Speaker Profile

Ph.D., M.D., Managing Partner, Sutter Hill

Jeff Bird focuses on healthcare, including biotechnology and medical devices.
Recent Series A investments include Forty Seven Inc. (monoclonal antibody immuno-oncology therapies) and XIOS Therapeutics (small molecular immuno-oncology.)  In the genomics space, Jeff is a co-investor with Illumina in Helix (consumer genomics marketplace) and GRAIL (cancer screening test). Jeff was CEO and an investor at Verinata Health (noninvasive prenatal diagnosis). He is currently a board member at Drais Pharmaceuticals, NuGen Technologies, Portola Pharmaceuticals, Restoration Robotics, and Threshold Pharmaceuticals. He also represents the firm’s investments in Acceleron Pharmaceuticals, Ameritox and Pacific Biosciences. Jeff was formerly a director at Horizon Pharma (HZNP), Akarx Inc., BARRX Medical, Inc., and Idun Pharmaceuticals. Jeff was previously Senior Vice President, Business Operations at Gilead Sciences. Jeff received a degree in Biological Sciences from Stanford in 1982, a Ph.D. in Cancer Biology in 1988 and a M.D. in 1992 from Stanford Medical School.

Don't Miss Important Precision Medicine Updates

PMWC is the most comprehensive precision medicine conference. To receive the lastest news and updates from the field, subscribe to the newsletter here.

View the top 3 talks from PMWC here (password: top-videos).